Louise Chen
Stock Analyst at Scotiabank
(3.41)
# 947
Out of 5,072 analysts
297
Total ratings
46.64%
Success rate
3.76%
Average return
Main Sectors:
Stocks Rated by Louise Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Sector Perform | $650 → $770 | $780.19 | -1.31% | 2 | Nov 24, 2025 | |
| SRPT Sarepta Therapeutics | Upgrades: Sector Outperform | $80 | $21.34 | +274.88% | 3 | Jun 6, 2025 | |
| ACRS Aclaris Therapeutics | Maintains: Sector Outperform | $15 → $9 | $2.83 | +218.02% | 6 | May 9, 2025 | |
| EWTX Edgewise Therapeutics | Downgrades: Sector Perform | $50 → $14 | $26.06 | -46.28% | 2 | Apr 3, 2025 | |
| GANX Gain Therapeutics | Initiates: Sector Outperform | $12 | $3.50 | +242.86% | 1 | Mar 7, 2025 | |
| INVA Innoviva | Initiates: Sector Outperform | $55 | $21.72 | +153.22% | 5 | Mar 7, 2025 | |
| PTCT PTC Therapeutics | Initiates: Sector Perform | $55 | $85.99 | -36.04% | 1 | Mar 7, 2025 | |
| CATX Perspective Therapeutics | Initiates: Sector Outperform | $15 | $2.35 | +538.30% | 1 | Mar 7, 2025 | |
| PVLA Palvella Therapeutics | Initiates: Sector Outperform | $50 | $102.79 | -51.36% | 1 | Mar 7, 2025 | |
| ARDX Ardelyx | Initiates: Sector Outperform | $15 | $5.82 | +157.95% | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $17 | $40.22 | -57.73% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $70 | $71.65 | -2.30% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $21.90 | +128.31% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $30 | $9.54 | +214.47% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $55 | $20.41 | +169.48% | 8 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.40 | - | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $160 | $49.35 | +224.21% | 20 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $49.61 | - | 6 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $240 | $227.70 | +5.40% | 6 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $45 | $25.74 | +74.83% | 31 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $215 | $206.92 | +3.90% | 40 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $8.48 | - | 5 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $155 | $104.83 | +47.86% | 25 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $20.83 | - | 9 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $885 | $1,075.47 | -17.71% | 45 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $7.16 | - | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $24.15 | - | 10 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $17.20 | - | 6 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $3.54 | - | 3 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $219.88 | - | 6 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.78 | - | 3 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.40 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $16.01 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.77 | - | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.70 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $3.42 | +1,800.58% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $2.81 | +77.94% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $14.42 | +246.74% | 3 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $30.65 | +63.13% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.67 | +199.40% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $9 | $0.39 | +2,235.24% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,687,500 | $1.35 | +124,999,900.00% | 1 | Jul 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $258 | $277.27 | -6.95% | 1 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $15 | $26.89 | -44.22% | 3 | Feb 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $1.16 | +4,210.34% | 2 | Jul 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.35 | +1,381.48% | 2 | Aug 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $8.05 | +459.01% | 1 | Jun 22, 2017 |
Regeneron Pharmaceuticals
Nov 24, 2025
Maintains: Sector Perform
Price Target: $650 → $770
Current: $780.19
Upside: -1.31%
Sarepta Therapeutics
Jun 6, 2025
Upgrades: Sector Outperform
Price Target: $80
Current: $21.34
Upside: +274.88%
Aclaris Therapeutics
May 9, 2025
Maintains: Sector Outperform
Price Target: $15 → $9
Current: $2.83
Upside: +218.02%
Edgewise Therapeutics
Apr 3, 2025
Downgrades: Sector Perform
Price Target: $50 → $14
Current: $26.06
Upside: -46.28%
Gain Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $12
Current: $3.50
Upside: +242.86%
Innoviva
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $21.72
Upside: +153.22%
PTC Therapeutics
Mar 7, 2025
Initiates: Sector Perform
Price Target: $55
Current: $85.99
Upside: -36.04%
Perspective Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $2.35
Upside: +538.30%
Palvella Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $102.79
Upside: -51.36%
Ardelyx
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $5.82
Upside: +157.95%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $17
Current: $40.22
Upside: -57.73%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $70
Current: $71.65
Upside: -2.30%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $21.90
Upside: +128.31%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $30
Current: $9.54
Upside: +214.47%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $20.41
Upside: +169.48%
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.40
Upside: -
Nov 6, 2024
Reiterates: Overweight
Price Target: $160
Current: $49.35
Upside: +224.21%
Nov 6, 2024
Reiterates: Overweight
Price Target: n/a
Current: $49.61
Upside: -
Oct 31, 2024
Maintains: Overweight
Price Target: $200 → $240
Current: $227.70
Upside: +5.40%
Oct 25, 2024
Reiterates: Overweight
Price Target: $45
Current: $25.74
Upside: +74.83%
Oct 16, 2024
Reiterates: Overweight
Price Target: $215
Current: $206.92
Upside: +3.90%
Oct 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.48
Upside: -
Oct 3, 2024
Reiterates: Overweight
Price Target: $155
Current: $104.83
Upside: +47.86%
Sep 19, 2024
Reiterates: Overweight
Price Target: n/a
Current: $20.83
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $885
Current: $1,075.47
Upside: -17.71%
Sep 16, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.16
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $24.15
Upside: -
Aug 29, 2024
Reiterates: Overweight
Price Target: n/a
Current: $17.20
Upside: -
Aug 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $3.54
Upside: -
Aug 14, 2024
Reiterates: Overweight
Price Target: n/a
Current: $219.88
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.78
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.40
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $16.01
Upside: -
May 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.77
Upside: -
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.70
Upside: -
Jan 31, 2024
Reiterates: Overweight
Price Target: $65
Current: $3.42
Upside: +1,800.58%
Sep 13, 2023
Reiterates: Overweight
Price Target: $5
Current: $2.81
Upside: +77.94%
Sep 5, 2023
Reiterates: Overweight
Price Target: $50
Current: $14.42
Upside: +246.74%
Aug 22, 2023
Reiterates: Overweight
Price Target: $50
Current: $30.65
Upside: +63.13%
Aug 17, 2023
Reiterates: Neutral
Price Target: $5
Current: $1.67
Upside: +199.40%
May 12, 2023
Maintains: Overweight
Price Target: $5 → $9
Current: $0.39
Upside: +2,235.24%
Jul 7, 2021
Initiates: Overweight
Price Target: $1,687,500
Current: $1.35
Upside: +124,999,900.00%
Mar 27, 2020
Maintains: Neutral
Price Target: $240 → $258
Current: $277.27
Upside: -6.95%
Feb 12, 2020
Maintains: Neutral
Price Target: $9 → $15
Current: $26.89
Upside: -44.22%
Jul 19, 2018
Maintains: Overweight
Price Target: $40 → $50
Current: $1.16
Upside: +4,210.34%
Aug 18, 2017
Initiates: Overweight
Price Target: $20
Current: $1.35
Upside: +1,381.48%
Jun 22, 2017
Initiates: Overweight
Price Target: $45
Current: $8.05
Upside: +459.01%